Recipharm, a leading global pharmaceutical contract development and manufacturing organisation (CDMO), has announced significant expansions to its pharmaceutical development capabilities through strategic investments and technology integration across its global network. The company is enhancing its services for both early and late-stage product development, including clinical study supply capabilities and commercial technologies.
The investments strengthen Recipharm's position as a fully integrated service provider covering the entire lifecycle of pharmaceutical products, from API route scouting to commercial manufacturing.
Global Development Network Enhancement
Recipharm's development centers, strategically positioned across Europe, the US, and India, have received substantial upgrades to their infrastructure and technological capabilities. These enhancements are guided by Quality by Design (QbD) principles, with experts utilizing the innovative ReciPredict platform that combines material and process sciences with statistical tools, modeling, and simulation to develop robust pharmaceutical products.
"By integrating scientific, regulatory, operational and commercial strategy from the outset we help our customers move faster, avoid costly delays and build confidence that their product submissions will meet and exceed agency requirements for critical medicines worldwide," explained Greg Behar, Recipharm's CEO.
Small Molecule Development Expansion
The company's center of excellence for small molecules in Bengaluru, India, has expanded its capabilities with a new laboratory dedicated to sterile product development. This complements recently established analytical laboratories focusing on Extractables and Leachables, Nitrosamines, and Elemental Impurities testing, which have become Recipharm's flagship location for comprehensive analytical services.
In Zwickau, Germany, Recipharm has enhanced its pilot-scale development center that specializes in dry granulation, tableting, and hard capsule filling, with particular expertise in combination products.
Both the Bengaluru and Zwickau facilities have received investments in advanced material characterization equipment, including a compression and compaction simulator, a Mini-Pactor for dry granulation, a pilot-scale capsule filler, and a small-scale tablet press.
Sterile Product Development Capabilities
The CDMO has significantly bolstered its pre-clinical, clinical, and pilot-scale sterile development capabilities for both small and large molecules. The expanded portfolio includes liquid vials, pre-filled syringes, blow-fill-seal, and lyophilized products.
Key investments in this area include:
- A new development laboratory for sterile formulations of small molecules in Bengaluru
- Installation of a GMP VarioSys line for vials and pre-filled syringes at the Wasserburg site
- GMP LAB+ equipment at the Kaysersberg facility
Biologics and Advanced Therapies
ReciBioPharm, the company's biologics and Advanced Therapy Medicinal Products (ATMP) development segment, operates from facilities in Watertown (US), Cuxhaven (Germany), and Lisbon (Portugal). The division's capabilities encompass monoclonal antibodies and recombinant proteins, while also advancing innovative medicines and supporting clinical trials for microbiome therapeutics, oncolytic viruses, nucleic acid (xRNA/LNP) technologies, viral vectors (AAV, Lentivirus), and bacterial vaccines and therapeutics.
API Development Services
Recipharm's site in Yavne, Israel, continues to provide integrated services from route scouting for new chemical entities to small-scale API production for toxicology studies, first-in-human trials, and early clinical supplies. The site also offers comprehensive impurity management and analytical services as part of its integrated offering.
Strategic Partnership with ProductLife Group
In a complementary move to enhance its service offerings, Recipharm has formed a strategic partnership with ProductLife Group (PLG) to accelerate time to clinical trials for pharmaceutical companies. This collaboration combines Recipharm's development and manufacturing capabilities with PLG's product development and regulatory expertise.
The partnership aims to help biopharma companies navigate from early-stage development to approval more efficiently while reducing supply chain, compliance, and regulatory challenges. For Recipharm's customers, this provides immediate access to PLG's global regulatory affairs, pharmacovigilance, and market access experience.
"As regulatory complexity grows, our clients need integrated solutions that connect strategy and execution. With Recipharm's 700 product development experts and over 400 projects delivered annually, this partnership allows us to embed regulatory thinking directly into product development and operational planning," said Xavier Duburcq, PLG's CEO.
Global Regulatory Excellence
All Recipharm development centers are equipped to support clinical trials across the US, EU, and other key regions, adhering to the highest regulatory standards. With fully integrated analytical capabilities across its network, Recipharm continues to support the development of new medicines with a commitment to quality and innovation.
The company achieves flexibility and agility through teams of experts strategically positioned across its global sites, including over 60 scientists dedicated to developing various dosage forms in Bengaluru and more than 150 scientists providing comprehensive analytical expertise. These teams collaborate with development experts at other sites to deliver global support and specialized knowledge.
These investments and partnerships position Recipharm to address the growing demand for integrated pharmaceutical development services that can navigate increasingly complex regulatory environments while accelerating time to market for critical medicines.
